FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022073998> ?p ?o ?g. }

• W2022073998 abstract "Editor, Several recent studies have found photodynamic therapy (PDT) to be beneficial in the treatment of chronic central serous chorioretinopathy (CSC) (Chan et al. 2008; Maier et al. 2008; Orobia et al. 2008). To the same end, bevacizumab has also been investigated as a treatment for CSC in a recent pilot study. Torres-Soriano and colleagues reported that five patients with CSC showed functional and anatomical improvement after treatment with intravitreal bevacizumab (Torres-Soriano et al. 2008). The present study investigated the efficacy of intravitreal bevacizumab compared with PDT to treat patients with chronic, recurrent types of CSC. This retrospective, nonrandomized, comparative case series included 29 patients who were considered to have chronic CSC when detachment of the macula persisted for at least 6 months or when the condition was associated with recurrent detachment. Patients with evidence of choroidal neovascularization were excluded after assessment by both indocyanine green angiography (ICGA) and fluorescein angiography (FA). No patient had a history of laser photocoagulation. Treatment modalities were selected by individual clinicians. In the bevacizumab-treated group, 16 patients received 1–7 intravitreal injections of bevacizumab (1.25 mg in 0.05 ml), guided by best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) findings at 4- to 6-week intervals. The mean number of injections was 3.5 (±2.0). In the PDT-treated group, 13 patients received PDT using the standard dose of verteporfin (6 mg/m2). All PDT-treated patients received only a single treatment. The mean follow-up time for the bevacizumab-treated group was 7.3 months (±3.7 months) and that for the PDT-treated group 5.9 months (±3.5 months). The study was approved by the Institutional Review Board of the Asan Medical Center. Table 1 shows the characteristics of the patients. In the bevacizumab-treated group, the mean Snellen BCVA improved from 0.49 to 0.66 and mean foveal thickness (FT) fell from 290 to 219 μm (p = 0.06 and p = 0.01, respectively). The PDT-treated group showed an improvement in mean Snellen BCVA from 0.43 at baseline to 0.65, and in mean FT from 332 to 171 μm, and 12 of 13 patients (92%) demonstrated complete resorption of subretinal fluid (SRF), at the 1-month follow-up visit. Seven of 13 eyes (53.8%) that underwent PDT had a FT of 171 μm or less. Such foveal thinning was thought to be associated with choriocapillary hypoperfusion in the PDT area, as shown by ICGA (Fig. 1). The eye of a 54-year-old man 3 months after treatment with photodynamic therapy (PDT). (A) Fundus photography. (B) Peak phase ICGA and (C) midphase ICGA show the area of choriocapillary hypoperfusion (3000 μm in width) after PDT. (D) OCT demonstrates absence of subretinal fluid but foveal thinning was evident. Unlike what was noted after PDT treatment, bevacizumab-treated eyes revealed a rather slow and fluctuating visual recovery and developed either disease recurrence (four eyes) or drug resistance (three eyes) following repeat injection. Although seven bevacizumab-treated eyes showed persistent fluid at the last follow-up visit, there was no significant difference in the mean final BCVA between the bevacizumab- and PDT-treated groups (p = 0.55) (Fig. 2). Comparison of the mean logMAR best-corrected visual acuity (BCVA) of patients treated with photodynamic therapy (blue line) or intravitreal bevacizumab injection (pink line) at the first month after treatment and at last follow-up. In the present study, intravitreal bevacizumab, used in selected patients, was as effective as was PDT in treating chronic CSC, but the mean visual acuity increased significantly more in PDT-treated than in bevacizumab-treated patients. In terms of safety, foveal thinning occurred less frequently in bevacizumab-treated eyes than in PDT-treated eyes (25% versus 53%). However, it is possible that the low incidence of foveal thinning in the bevacizumab-treated group is attributable to the fact that bevacizumab treatment was not as effective as PDT. In addition, foveal thinning could be partly caused by the significantly longer macular detachment period evident in the PDT-treated group. In conclusion, despite showing a slower and rather incomplete reduction in SRF, intravitreal bevacizumab seemed to be a safer and effective treatment option, compared with PDT, in selected patients; however, our results need to be further explored in studies with more patients and longer follow-up times. The authors have no proprietary or commercial interest in any materials discussed in the article" @default.
• W2022073998 created "2016-06-24" @default.
• W2022073998 creator A5011227177 @default.
• W2022073998 creator A5042433884 @default.
• W2022073998 creator A5044685974 @default.
• W2022073998 creator A5048382900 @default.
• W2022073998 creator A5083736101 @default.
• W2022073998 date "2011-04-18" @default.
• W2022073998 modified "2023-10-17" @default.
• W2022073998 title "Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy" @default.
• W2022073998 cites W2029229066 @default.
• W2022073998 cites W2085345878 @default.
• W2022073998 cites W4236318004 @default.
• W2022073998 doi "https://doi.org/10.1111/j.1755-3768.2009.01835.x" @default.
• W2022073998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20346078" @default.
• W2022073998 hasPublicationYear "2011" @default.
• W2022073998 type Work @default.
• W2022073998 sameAs 2022073998 @default.
• W2022073998 citedByCount "23" @default.
• W2022073998 countsByYear W20220739982012 @default.
• W2022073998 countsByYear W20220739982013 @default.
• W2022073998 countsByYear W20220739982014 @default.
• W2022073998 countsByYear W20220739982015 @default.
• W2022073998 countsByYear W20220739982017 @default.
• W2022073998 countsByYear W20220739982018 @default.
• W2022073998 countsByYear W20220739982019 @default.
• W2022073998 countsByYear W20220739982023 @default.
• W2022073998 crossrefType "journal-article" @default.
• W2022073998 hasAuthorship W2022073998A5011227177 @default.
• W2022073998 hasAuthorship W2022073998A5042433884 @default.
• W2022073998 hasAuthorship W2022073998A5044685974 @default.
• W2022073998 hasAuthorship W2022073998A5048382900 @default.
• W2022073998 hasAuthorship W2022073998A5083736101 @default.
• W2022073998 hasBestOaLocation W20220739981 @default.
• W2022073998 hasConcept C118487528 @default.
• W2022073998 hasConcept C126322002 @default.
• W2022073998 hasConcept C141071460 @default.
• W2022073998 hasConcept C150173356 @default.
• W2022073998 hasConcept C178790620 @default.
• W2022073998 hasConcept C185592680 @default.
• W2022073998 hasConcept C2776694085 @default.
• W2022073998 hasConcept C2777802072 @default.
• W2022073998 hasConcept C2778257484 @default.
• W2022073998 hasConcept C2780248432 @default.
• W2022073998 hasConcept C2781148688 @default.
• W2022073998 hasConcept C2781323092 @default.
• W2022073998 hasConcept C2781359195 @default.
• W2022073998 hasConcept C71924100 @default.
• W2022073998 hasConceptScore W2022073998C118487528 @default.
• W2022073998 hasConceptScore W2022073998C126322002 @default.
• W2022073998 hasConceptScore W2022073998C141071460 @default.
• W2022073998 hasConceptScore W2022073998C150173356 @default.
• W2022073998 hasConceptScore W2022073998C178790620 @default.
• W2022073998 hasConceptScore W2022073998C185592680 @default.
• W2022073998 hasConceptScore W2022073998C2776694085 @default.
• W2022073998 hasConceptScore W2022073998C2777802072 @default.
• W2022073998 hasConceptScore W2022073998C2778257484 @default.
• W2022073998 hasConceptScore W2022073998C2780248432 @default.
• W2022073998 hasConceptScore W2022073998C2781148688 @default.
• W2022073998 hasConceptScore W2022073998C2781323092 @default.
• W2022073998 hasConceptScore W2022073998C2781359195 @default.
• W2022073998 hasConceptScore W2022073998C71924100 @default.
• W2022073998 hasIssue "3" @default.
• W2022073998 hasLocation W20220739981 @default.
• W2022073998 hasLocation W20220739982 @default.
• W2022073998 hasOpenAccess W2022073998 @default.
• W2022073998 hasPrimaryLocation W20220739981 @default.
• W2022073998 hasRelatedWork W1123117347 @default.
• W2022073998 hasRelatedWork W1192632716 @default.
• W2022073998 hasRelatedWork W1615644543 @default.
• W2022073998 hasRelatedWork W2036520195 @default.
• W2022073998 hasRelatedWork W2078951251 @default.
• W2022073998 hasRelatedWork W2333560032 @default.
• W2022073998 hasRelatedWork W2396155251 @default.
• W2022073998 hasRelatedWork W2397594239 @default.
• W2022073998 hasRelatedWork W2991715136 @default.
• W2022073998 hasRelatedWork W4242893149 @default.
• W2022073998 hasVolume "89" @default.
• W2022073998 isParatext "false" @default.
• W2022073998 isRetracted "false" @default.
• W2022073998 magId "2022073998" @default.
• W2022073998 workType "article" @default.